ClinicalTrials.gg
CompletedNCT05265676Updated Mar 3, 2022

Bioequivalence Study of a Generic Enoxaparin Sodium to Clexane® After Single Subcutaneous Dose in Healthy Human Subjects

A Phase 1 interventional study of Enoxaparin Sodium (Venus Remedies Limited) and Enoxaparin Sodium (Sanofi) in Healthy, sponsored by Venus Remedies Limited. Completed at 1 site in India. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-03-03.

Sponsored by Venus Remedies Limited · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 11 months after the study started (first participant enrolled Feb 2021, registered Feb 2022).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 45 Years
Sex
All
01

Study summary

This is a single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced, pharmacodynamic (PD) study with 7 days wash-out period. The objective of this study is to assess the bioequivalence between the Enoxaparin (Venus Remedies Limited, India) and its innovator product (Clexane®, Sanofi, Germany).

Read the detailed description

Enoxaparin is a widely used low-molecular-weight heparin (LMWH) obtained by alkaline β-eliminative cleavage of heparin benzyl ester derived from the porcine intestinal mucosa. Currently, several biosimilars/generics of LMWHs with differing potencies are being developed and marketed in various parts of the world. They differ in their PK and PD properties, which could be possibly due to the depolymerization processes or the manufacturing methods that result in its structural variability. Therefore, it is important that the potency of each biosimilar LMWH be compared with its innovator's molecule.

The PK properties and bioavailability of LMWHs are routinely determined by pharmacodynamic (PD) surrogates such as Anti-Xa activity, Anti-IIa activity, tissue factor pathway inhibitor (TFPI) and activated partial thromboplastin time (aPTT).

This study was designed as a double-blind, randomized, two-period, two-treatment, two-sequence, crossover, balanced, single-dose pharmacodynamic study in healthy, adult, human subjects under fasting conditions to compare and evaluate the pharmacodynamic profile of test product [Enoxaparin Sodium prefilled syringe BP; 40 mg/0.4 mL (Venus Remedies Limited, India)] with that of reference product ['Clexane®' Enoxaparin Sodium prefilled syringe; 40 mg/0.4 mL (Sanofi, Germany)]. The study was conducted with 24 subjects in accordance with protocol.

After overnight fasting of at least 08 hours, a single dose of either test product or reference product was administered to the subjects slowly by subcutaneous route (shaved abdominal wall) alternated in both period between left or right anterolaterally in a supine posture under the supervision of trained study personnel.

The subjects received the test product (A) and reference product (B) in the study as per the randomization schedule. Participants were randomly selected for one of the two sequences: either AB or BA. The washout period between administration of study drugs in each period was 7 days. Blood samples to assess PD parameters were collected in both study periods at the following time points: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after dosing.

The Anti-Xa and Anti-IIa activity was measured by the chromogenic method using commercial reagent kits - STA®-liquid Anti-Xa, Diagnostica Stago and Actichrome® Heparin (Anti-IIa) kit, Biomedica Diagnostics, respectively. TFPI was assessed using Enzyme-Linked Immunosorbent Assay (ELISA) kit (Quantikine® Human TFPI ELISA kit) and aPTT was determined using clotting assay reagent kit - STA-C.K. Prest® 5-Diagnostica Stago.

Statistical analysis was performed on the pharmacodynamic data to assess bioequivalence between the test product to the reference product. The average bioequivalence of the products was concluded if two-sided 90% CI for the test to the reference ratio of the population means was within 80% and 125% interval for each of the Ln-transformed data, Amax and AUECt for Anti-Xa and Anti-IIa (primary objective).

02

Conditions studied

  • Healthy

Keywords

  • enoxaparin
  • low molecular weight heparin
  • bioequivalence
  • anticoagulant
  • antithrombotic
  • heparin
  • pharmacodynamic equivalence
03

In context

Lead sponsor

Venus Remedies Limited is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 45 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:- Volunteers must fulfill all of the following inclusion criteria to be eligible for participation in the study, unless otherwise specified.

  1. Age: 18 to 45 years old, both inclusive.
  2. Gender: Male and/or non-pregnant, non-lactating female.

    A. Female of must have a negative serum beta human chorionic gonadotropin (β-HCG) pregnancy test performed within 28 days prior to first dosing day. They must be using an acceptable form of .

    B. For female of childbearing potential, acceptable forms of contraception include the following:

    i. Non hormonal intrauterine device in place for at least 3 months prior to the start of the study and remaining in place during the study period, or

    ii. Barrier methods containing or used in conjunction with a spermicidal agent, or

    iii. Surgical sterilization or

    iv. Practicing sexual abstinence throughout the course of the study.

    C. Female will not be considered of childbearing potential if one of the following is reported and documented on the medical history:

    i. with spontaneous amenorrhea for at least one year, or

    ii. Bilateral oophorectomy with or without a hysterectomy and an absence of bleeding for at least 6 months, or

    iii. Total hysterectomy and an absence of bleeding for at least 3 months.

  3. : 18.5 to 30.0 kg/m2, both inclusive; BMI value should be rounded off to one significant digit after decimal point (e.g. 30.04 rounds down to 30.0, while 18.45 rounds up to 18.5).
  4. Volunteer with at least 50 kg weight
  5. Able to read \& understand document and give written informed consent to participate in the study
  6. Non-smokers and non-tobacco users (i.e. having no past history of smoking and tobacco consuming for at least one year prior to study)
  7. Non-alcoholic users will be eligible to participate in this study (i.e. having no past history of drinking alcohol for at least one year prior to study).
  8. Able to communicate effectively with study personnel.
  9. Willing to provide written informed consent to participate in the study.
  10. All volunteers must be judged by the principal or sub-investigator or physician as normal and healthy during a pre-study safety assessment performed within 28 days of the first dose of study medication which will include:

    1. A physical examination (clinical examination) with no finding.
    2. Results within normal limits or clinically non-significant for the following tests: haematology, biochemistry, serology, coagulogram and urinalysis

Exclusion Criteria:-

Volunteers must not be enrolled in the study if they meet any one of the following criteria:

  1. History of or idiosyncratic reaction to Enoxaparin Sodium, pork, heparin or its derivatives, other low molecular weight heparins or other related drugs, or any of its formulation ingredients.
  2. Have significant diseases or clinically significant abnormal findings during screening [medical history, physical examination (clinical examination), laboratory evaluations, , chest X-ray recording, obstetrics and gynecological history and examination (for female volunteers)].
  3. Any disease or condition like diabetes, psychosis or others, which might compromise the haemopoeitic, gastrointestinal, renal, hepatic, cardiovascular, respiratory, central nervous system or any other body system.
  4. History or presence of bronchial asthma.
  5. Use of any hormone replacement therapy within 3 months prior to the first dose of study medication.
  6. A depot injection or implant of any drug within 3 months prior to the first dose of study medication.
  7. Use of CYP enzyme inhibitors or inducers within 30 days prior to the first dose of study medication (see http://medicine.iupui.edu/clinpharm/ddis/main-table).
  8. History or evidence of drug dependence.
  9. History of difficulty with donating blood or difficulty in accessibility of veins.
  10. A positive hepatitis screen (includes subtypes B \& C).
  11. A positive test result for antibody and / or syphilis (RPR).
  12. Volunteers who have received a known or equivalent to this drug within seven elimination half-life of the administered drug prior to the first dose of study medication.
  13. Volunteers who have donated blood or loss of blood 50 ml to 100 ml within 30 days or 101 ml to 200 ml within 60 days or >200 ml within 90 days (excluding volume drawn at screening for this study) prior to first dose of study medication, whichever is greater.
  14. Intolerance to venipuncture
  15. Any food allergy, intolerance, restriction or special diet that, in the opinion of the principal investigator or sub-investigator, could contraindicate the volunteer's participation in this study.
  16. Institutionalized volunteers.
  17. Use of any prescribed medications within 14 days prior to the first dose of study medication.
  18. Use of any OTC products, vitamin and herbal products, etc., within 7 days prior to the first dose of study medication.
  19. Use of grapefruit and grapefruit containing products within 7 days prior to the first dose of study medication.
  20. Ingestion of any caffeine or xanthine products (i.e. coffee, tea, chocolate, and caffeine-containing sodas, colas, etc.), recreational drugs within 48 hours prior to the first dose of study medication.
  21. Ingestion of any unusual diet, for whatever reason (e.g.: low sodium) for three weeks prior to the first dose of study medication.
  22. History or presence of active major bleeding.
  23. History or presence of Thrombocytopenia.
  24. Volunteer having count lower than lower limit of normal range during screening.
  25. Volunteer having and Activated Partial Thromboplastin Time 1.1 times higher than the during screening.
  26. Volunteer having INR outside of normal range during screening.
  27. Presence of minor bleeding episodes such as epistaxis, rectal bleeding and gingival bleeding.
  28. Volunteers with history of stomach ulcer/duodenal ulcer/intestinal ulcers.
  29. Volunteers have undergone any surgery in recent past.
  30. Volunteers with the history of piles and fissure.
  31. Volunteer having any tattoo or any other type of scar at site of injection.
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Experimental
    Cohort 1 - AB treatment sequence

    Period 1 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India. Period 2 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany.

    Drug: Enoxaparin Sodium (Venus Remedies Limited) · Drug: Enoxaparin Sodium (Sanofi)

  • Experimental
    Cohort 2 - BA treatment sequence

    Period 1 - Reference Product (B): 'Clexane®' (Enoxaparin Sodium pre-filled syringe; 40 mg/0.4 ml) of Sanofi, Germany. Period 2 - Test Product (A): Enoxaparin Sodium pre-filled syringe BP 40 mg/0.4 ml of Venus Remedies Limited, India.

    Drug: Enoxaparin Sodium (Venus Remedies Limited) · Drug: Enoxaparin Sodium (Sanofi)

Interventions

06

What researchers measure

Primary outcomes

  1. Amax for Anti-Xa and Anti-IIa

    Maximum measured Anti-Xa and Anti-IIa plasma activity over the time span specified

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

  2. AUECt for Anti-Xa and Anti-IIa

    The area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method, for Anti-Xa and Anti-IIa

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

Secondary outcomes

  1. AUECi for Anti-Xa and Anti-IIa

    The area under the activity/concentration-time curve from time 0 extrapolated to infinity, for Anti-Xa and Anti-IIa

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

  2. Tmax for Anti-Xa and Anti-IIa

    Tmax is the time to Amax for Anti-Xa and Anti-IIa

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

  3. t1/2 for Anti-Xa and Anti-IIa

    apparent first order terminal elimination half-life for Anti-Xa and Anti-IIa

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

  4. Kel for Anti-Xa and Anti-IIa

    The terminal elimination rate constant obtained from the slope of the line, fitted by linear least squares regression, through the terminal points of the log (base e) of the activity versus time plot for these points

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

  5. Amax for ratio of Anti-Xa/Anti-IIa activity, TFPI (Baseline corrected and baseline uncorrected) and aPTT (Baseline corrected and baseline uncorrected).

    Maximum activity for ratio of Anti-Xa/Anti-IIa and TFPI over the time span specified; maximum clotting time for aPTT

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

  6. AUECt for ratio of Anti-Xa/Anti-IIa activity, TFPI (Baseline corrected and baseline uncorrected) and aPTT (Baseline corrected and baseline uncorrected)

    The area under the plasma activity/concentration-time curve from the time 0 to the last measurable concentration, as calculated by the linear trapezoidal method, for ratio of Anti-Xa/Anti-IIa activity, TFPI (Baseline corrected and baseline uncorrected) and aPTT (Baseline corrected and baseline uncorrected)

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

  7. AUECi for ratio of Anti-Xa/Anti-IIa activity and TFPI (Baseline corrected and baseline uncorrected)

    AUC0-inf is the area under the activity/concentration-time curve from time 0 extrapolated to infinity, for ratio of Anti-Xa/Anti-IIa activity and TFPI (Baseline corrected and baseline uncorrected)

    Time frame: pre-dose (0.0 hour) and at 0.5, 1.0, 1.5, 2.0, 2.333, 2.667, 3.0, 3.333, 3.667, 4.0, 4.5, 5.0, 6.0, 8.0, 10.0, 12.0, 16.0, and 24.0 hours after drug administration

07

Study locations

1 site
  • Cliantha Research Limited
    Ahmedabad, Gujarat 380054, India
08

References and documents

Publications

  • Saxena S, Chaudhary M, Chaudhary S, Aggarwal A. Bioequivalence of a biosimilar enoxaparin (Cloti-Xa) and its innovator (Clexane(R) ): A single-dose, randomized, double-blind, two-period, two-treatment, two-sequence, crossover, balanced study in healthy human subjects. Pharmacol Res Perspect. 2022 Aug;10(4):e00979. doi: 10.1002/prp2.979. PubMed 35762448 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2021 to primary completion in Mar 2021, 0 months.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 22, 2022
First posted
Mar 3, 2022
StartActual
Feb 26, 2021
Primary completionActual
Mar 7, 2021
CompletionActual
Mar 11, 2021
Last update
Mar 3, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 3, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05265676
Lead sponsor
Venus Remedies Limited
Responsible party
Sponsor
First posted
Mar 3, 2022
Start date
Feb 26, 2021
Primary completion
Mar 7, 2021
Completion
Mar 11, 2021
Last update
Mar 3, 2022

Study contacts

Dr. Mayur Soni
principal investigator · Cliantha Research Limited, India

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Enoxaparin sodium

Start the discussion